Literature DB >> 5030578

Survival of hematopoietic and leukemic colony-forming cells in vivo following the administration of daunorubicin or adriamycin.

A Razek, F Valeriote, T Vietti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 5030578

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  7 in total

Review 1.  A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy.

Authors:  R Abraham; R L Basser; M D Green
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

Review 2.  Clinical pharmacokinetics of doxorubicin.

Authors:  P A Speth; Q G van Hoesel; C Haanen
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

3.  Comparative toxicity of detorubicin and doxorubicin, free and DNA-bound, for hemopoietic stem cells.

Authors:  M Huybrechts; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

4.  A phase II study of high dose epirubicin in unresectable non small cell lung cancer.

Authors:  E F Smit; H H Berendsen; D A Piers; J Smeets; A Riva; P E Postmus
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

5.  Cytotoxic effect of dose and schedule on normal murine hematopoietic progenitor cells following the administration of 4'-deoxydoxorubicin.

Authors:  I Pannacciulli; C Muzzulini; G Massa; G Bogliolo
Journal:  Br J Cancer       Date:  1984-11       Impact factor: 7.640

6.  Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM).

Authors:  G Colucci; S Romito; V Gebbia; G Pacilio; F Giotta; A Testa; G Pezzella; E Durini; B Agostara; S Cariello
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

7.  Renal and haemopoietic proliferative defects as a delayed consequence of cis-platin, adriamycin and daunomycin treatments.

Authors:  P G Braunschweiger; C J Kovacs; L L Schenken
Journal:  Br J Cancer       Date:  1982-03       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.